Lung cancer is a major health problem in the in the Asia-Pacific, with the region accounting for over 60% of global lung cancer diagnoses and deaths. Compared to Western counterparts, lung cancer in Asia exhibits distinct and unique characteristics. Key differences between lung cancer in Asia and outside Asia include a much higher prevalence in never-smokers, younger age of onset, and significantly higher rates of EGFR mutations (30-40% vs. 7-15% in the West). Over 30% of Asian lung cancer patients are never-smokers, with that number rising to over 50% in East Asian women. This is significantly higher than in Western countries. Asian patients have a much higher prevalence of EGFR mutations (30-40%) compared to Caucasian patients (7-15%). Conversely, KRAS mutations which are commonly smoking-related are less frequent in Asian patients (8-10%) than in Western populations (20-30%). While smoking is still a major cause, especially in men (half of the world's smokers live in Asia), never-smoker cases are highly driven by indoor air pollution (biomass fuel), ambient particulate matter (PM2.5), and passive smoking. Asian patients are generally diagnosed at a younger age, with early-onset lung cancer incidents rising, particularly in China, India, and Indonesia. Adenocarcinoma is the most common histological subtype in Asia, often appearing as ground-glass opacities. Asian patients tend to have a better prognosis. However, access to molecular diagnostics and newer, more effective treatments varies significantly between high-income countries (e.g., Japan, South Korea, Australia) and low-to-middle-income countries in the region.